Unicycive Therapeutics (UNCY) is back in focus after the US Food and Drug Administration issued a Complete Response Letter on its resubmitted New Drug Application for oxylanthanum carbonate, keeping approval on hold over third party manufacturing issues.

The FDA letter and the recent expansion of Unicycive Therapeutics' at-the-market program have coincided with sharp share price swings, including a 12.58% 1-day share price return, but 7-day and 30-day share price returns that declined 33.08% and 30.53% respectively. The 1-year total shareholder return is up 13.79%, while the 3-year total shareholder return is down 53.68%. This suggests that short-term momentum is weak despite a still positive 1-year outcome.

If this kind of volatility has you looking beyond a single biotech story, it can be useful to see what else is moving across the market through the 39 healthcare AI stocks.

With Unicycive Therapeutics trading at a sharp intrinsic discount and sitting far below the consensus price target, investors now face a key question: is the stock mispriced, or is the market already factoring in its future potential?

Most Popular Narrative: 75.5% Undervalued

Against the last close at $5.28, the most followed narrative for Unicycive Therapeutics points to a fair value of $21.53, implying a very large gap between price and narrative-based expectations.

Unicycive can potentially be a US$500m drug in 2029. Take the analysis we used above of 450,000 patients where OLC gets 4% to 5% market share in the third year after launch, but where the drug is priced at only US$2,000 per month. This suggests a US$500m revenue level. We think the US$500m assumption is conservative and accounts for the post-2028 market environment that would see lower pricing pressure, but higher patient uptake given the clinical effectiveness.

Curious what turns that revenue scenario into a $21.53 fair value for Unicycive Therapeutics? The narrative leans heavily on rapid revenue build, improving margins and a future earnings multiple usually seen in larger biotech stocks.

Result: Fair Value of $21.53 (UNDERVALUED)

However, that narrative could be upended if the FDA raises fresh concerns or if Unicycive Therapeutics sees slower than expected uptake for oxylanthanum carbonate.

Another View: What Multiples Say About Unicycive Therapeutics

The narrative and discount to fair value suggest Unicycive Therapeutics looks cheap, but the market is sending a different signal. The stock trades on a P/B of 3.7x, while both the US biotechs industry and its peer group sit at 2.7x, which points to a richer valuation and higher downside risk if expectations cool.

For investors, that kind of premium can be interpreted as confidence in the story or as a warning that a lot of hope is already priced in. The real question is which side of that trade you want to be on.

Next Steps

With sentiment clearly split on Unicycive Therapeutics, this is a moment to look directly at the facts, weigh both sides, and act on your own judgment using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Unicycive Therapeutics?

If Unicycive Therapeutics has you thinking more broadly about opportunities, use this moment to scan other stock ideas that could fit your goals before the crowd moves on.

• Target potential mispricing by reviewing companies highlighted in the 41 high quality undervalued stocks.
• Prioritize resilience by considering businesses featured in the 73 resilient stocks with low risk scores.
• Hunt for future standouts by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.